Sparstolonin B based pharmaceutical agent for neuroblastoma treatment
Use of sparstolonin B in inhibition of growth and/or viability of human neuroblastoma cells is described. The sparstolonin B can be naturally derived from the Chinese herb Sparganium stoloniferum or can be synthetic. The sparstolonin B is shown to be effective both in vitro and in vivo in inhibition of growth and/or viability of neuroblastoma cells of multiple different genetic backgrounds including N-myc amplified with wild p53 neuroblastoma cells, N-myc amplified with mutated p53 neuroblastoma cells, and N-myc nonamplified neuroblastoma cells.
1. A method for inhibiting the viability of neuroblastoma cells in vitro, the method comprising contacting a neuroblastoma cell culture with sparstolonin B, wherein the sparstolonin B contacts the cells at a concentration of about 10 micromolar or greater, wherein upon contact, the neuroblastoma cells exhibit cell death.
2. The method of claim 1 , the neuroblastoma cells including one or more of N-myc amplified with wild p53 cells, N-myc amplified with mutated p53 cells, and N-myc nonamplified cells.
3. The method of claim 1 , wherein the sparstolonin B is purified natural sparstolonin B.
4. The method of claim 1 , wherein the sparstolonin B is synthetic sparstolonin B.
5. The method of claim 1 , wherein the sparstolonin B is at a purity level of about 90% or greater.
6. The method of claim 1 , wherein the sparstolonin B is 100% pure sparstolonin B.
7. The method of claim 1 , wherein the sparstolonin B contacts the cells at a concentration of from about 10 micromolar to about 100 micromolar.
8. The method of claim 1 , wherein the neuroblastoma cells comprise one or more of IMR-32 cells, NGP cells, SKN-BE(2) cells, SKNF-1 cells, or SH-SY5Y cells.
9. The method of claim 1 , wherein the neuroblastoma cells comprise N-myc amplified neuroblastoma cells.
10. The method of claim 1 , wherein the neuroblastoma cells comprise N-myc non-amplified neuroblastoma cells.
11. A method for treating neuroblastoma comprising delivering a composition to neuroblastoma cells of a subject in need thereof, wherein the composition consists of sparstolonin B as the sole active pharmaceutical agent, wherein upon delivery the neuroblastoma cells exhibit cell death.
12. The method of claim 11 , wherein the composition is delivered to the subject at a sparstolonin dosage of from about 5 mg/kg/day to about 20 mg/kg/day.
13. The method of claim 11 , wherein the composition is a solid.
14. The method of claim 13 , wherein the composition is administered orally.
15. The method of claim 11 , wherein the composition is a liquid.
16. The method of claim 15 , wherein the composition is administered orally or parenterally.
17. The method of claim 11 , wherein the composition is delivered via a timed release or sustained release delivery system.
18. The method of claim 11 , wherein the method further comprises one or more of chemotherapy, radiotherapy, or surgical intervention.